Results 31 to 40 of about 418,602 (269)

Carcinomas and Carcinoid Tumors of the Lungs and Bronchi in Children and Adolescents: The EXPeRT Recommendations

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Primary lung carcinomas and bronchial carcinoid tumors (BC) are very rare malignancies in childhood. While typical BC and mucoepidermoid carcinomas are mostly low‐grade, localized tumors with a more favorable prognosis than in adults, necessitating avoidance of overtreatment, adenocarcinomas of the lung are often diagnosed at advanced disease ...
Michael Abele, Calogero Virgone, Michaela Kuhlen, Sabine Irtan, Yves Reguerre, Malgorzata Krawczyk, Ewa Bien, Tal Ben‐Ami, Maja Cesen, Ricardo Lopez‐Almaraz, Andrea Ferrari, Gianni Bisogno, Dominik T. Schneider, Abbas Agaimy, Constantin Lapa, Hubert Ducou le Pointe, Rainer Claus, Catherine Daniel, Ines B. Brecht, Daniel Orbach   +19 more
wiley   +1 more source

Cancer-associated fibroblasts promote osimertinib resistance in non-small cell lung cancer cells via METTL1-mediated NET1 m7G modification

Cell Death and Disease
Osimertinib resistance remains a major challenge in the treatment of non-small cell lung cancer (NSCLC). Cancer-associated fibroblasts (CAFs) are the most abundant stromal cells in tumor microenvironment (TME), however, its role in osimertinib resistance
Yongmei Qian, Zhiyuan Gong, Yidan Jia, Qicheng Zhang, Limin Cao, Bingbing Li, Jiayi Zhang, Min Wang, Xiang Wu, Ke Xu   +9 more
doaj   +1 more source

Construction and Expression of nm23-H1 Gene with Different Enzyme Activities and Resistant Specific shRNA in Eukaryotic Expression Vector

Chinese Journal of Lung Cancer, 2014
Background and objective It has been proven that nm23-H1 gene was a tumor metastatic suppressor gene. However, it’s molecular mechanism of suppressing metastasis remains unexplored.
Zhansheng LU, Lili GUO, Lin LI, Zhihao WU, Qinghua ZHOU   +4 more
doaj   +1 more source

Systematic pan-cancer analysis showed that RAD51AP1 was associated with immune microenvironment, tumor stemness, and prognosis

Frontiers in Genetics, 2022
Although RAD51 associated protein 1 (RAD51AP1) is crucial in genome stability maintenance, it also promotes cancer development with an unclear mechanism.
Renwang Liu, Renwang Liu, Guangsheng Zhu, Guangsheng Zhu, Mingbiao Li, Peijun Cao, Peijun Cao, Xuanguang Li, Xuanguang Li, Xiuwen Zhang, Xiuwen Zhang, Hua Huang, Hua Huang, Zuoqing Song, Zuoqing Song, Jun Chen, Jun Chen   +16 more
doaj   +1 more source

Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background The United Kingdom relapsed Wilms tumour (UKW‐R) trial aimed to improve the historically low survival rates after relapse of Wilms tumour (WT) through a prospective national risk‐stratified protocol. The trial also evaluated efficacy and toxicity of high‐dose melphalan.
Sucheta J. Vaidya, Veronica Moroz, Juliet Hale, Vesna Pavasovic, Rachel Hobson, Patricia Sartori, Daniel Saunders, Mark Powis, Gordan M. Vujanic, Stephen Baker, Kathy Pritchard‐Jones   +10 more
wiley   +1 more source

A Highly Efficient In Vitro Site-directed Mutagenesis Protocol for Introducing 
Multiple-site Mutations into Target Genes

Chinese Journal of Lung Cancer, 2014
Background and objective The methods for introducing point mutations into target genes are important for dissecting the relationship of gene structure and function. Up to date, there are numbers of protocols available for the purpose.
Fanrong MENG, Chen CHEN, Yongwen LI, Haisu WAN, Qinghua ZHOU   +4 more
doaj   +1 more source

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman, Madeleine King, Rajen Mody, Sara‐Jane Onyeama, Araz Marachelian, Thomas Cash, Sara M. Federico, Meaghan Granger, Ami V. Desai, Suzanne Shusterman, Jennifer H. Foster, Elizabeth Sokol, Chelsee Greer, Keri Streby, Holly J. Meany, Kieuhoa T. Vo, Margaret E. Macy, Rochelle Bagatell   +17 more
wiley   +1 more source

Comprehensive analyses of one-carbon metabolism related genes and their association with prognosis, tumor microenvironment, chemotherapy resistance and immunotherapy in lung adenocarcinoma

Frontiers in Molecular Biosciences, 2022
Background: Lung adenocarcinoma (LUAD) is the most common type of lung cancer and is a global public health concern. One-carbon (1C) metabolism plays a crucial role in the occurrence and development of multiple cancer types.
Ning Zhou, Ning Zhou, Quanying Tang, Quanying Tang, Haochuan Yu, Haochuan Yu, Tong Li, Tong Li, Fan Ren, Fan Ren, Lingling Zu, Lingling Zu, Gang Chen, Gang Chen, Jun Chen, Jun Chen, Song Xu, Song Xu   +17 more
doaj   +1 more source

Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma occurring most commonly in adolescence and young adulthood. Methods We present the clinical characteristics, treatments, and outcomes of patients with newly diagnosed ASPS enrolled on the Children's Oncology Group study ARST0332.
Jacquelyn N. Crane, Wei Xue, Amira Qumseya, Thomas Scharschmidt, Kathryn R. Tringale, Oscar Lopez Nunez, Jiaqi Hu, Donald A. Barkauskas, Rajkumar Venkatramani, Sheri L. Spunt, Aaron R. Weiss, Noah C. Federman   +11 more
wiley   +1 more source

Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation

Frontiers in Immunology, 2022
BackgroundAlthough immune checkpoint inhibitors (ICIs) are one of the most important treatments for advanced-stage non-small-cell lung cancer (NSCLC), NSCLC patients with ALK-rearranged usually don’t obtain a clinical benefit.
Bo Zhang, Bo Zhang, Jingtong Zeng, Jingtong Zeng, Hao Zhang, Hao Zhang, Shuai Zhu, Shuai Zhu, Hanqing Wang, Hanqing Wang, Jinling He, Jinling He, Lingqi Yang, Lingqi Yang, Ning Zhou, Ning Zhou, Lingling Zu, Lingling Zu, Xiaohong Xu, Zuoqing Song, Zuoqing Song, Song Xu, Song Xu   +22 more
doaj   +1 more source